drugset / Trial / NCT06451913
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
Timeline
- Start
- 2025-07-16
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saccharomyces boulardii CNCM I-745 | Other / unclassified | 500 mg | Oral |
| Background | Amoxicillin | Other / unclassified | 1000 mg | Oral |
Indications
No indication recorded.